Glutaminergic Agents for Cocaine Abuse - 5
Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT00000280
Collaborator
National Institute on Drug Abuse (NIDA) (NIH), VA Connecticut Healthcare System (U.S. Fed)
0
1
59
0
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate glutaminergic agents for cocaine abuse.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Glutaminergic Agents for Cocaine Abuse
Study Start Date
:
Sep 1, 1994
Actual Primary Completion Date
:
Aug 1, 1999
Actual Study Completion Date
:
Aug 1, 1999
Outcome Measures
Primary Outcome Measures
- Cocaine effects []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VA Connecticut Healthcare System | New Haven | Connecticut | United States | 06519 |
Sponsors and Collaborators
- Yale University
- National Institute on Drug Abuse (NIDA)
- VA Connecticut Healthcare System
Investigators
- Principal Investigator: Thomas R Kosten, M.D., VA Connecticut Healthcare System
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT00000280
Other Study ID Numbers:
- NIDA-09250-5
- P50DA009250
- P50-09250-5
First Posted:
Sep 21, 1999
Last Update Posted:
Apr 25, 2017
Last Verified:
Dec 1, 2002
Keywords provided by Yale University
Additional relevant MeSH terms: